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Abstract: Primary open angle glaucoma is a chronic optic neuropathy often requiring lifelong 
treatment. Patient compliance, adherence and persistence with therapy play a vital role in improved 
outcomes by reducing morbidity and the economic consequences that are associated with disease 
progression. A literature review including searches of The Cochrane Library, MEDLINE, 
PubMed, conference proceedings, and bibliographies of identiﬁ  ed articles reveals the enormous 
public health burden in various populations due to the impact of glaucoma associated visual 
impairment on the overall quality of life eg, fear of blindness, inability to work in certain occu-
pations, driving restrictions, motor vehicle accidents, falls, and general health status. Providing 
speciﬁ  c deﬁ  nitions for the frequently misunderstood terms “compliance, persistence and adher-
ence” with reference to medication use is central not only for monitoring patients’ drug dosing 
histories and clinical outcomes but also for subsequent research. In this review article, a summary 
of the advantages/disadvantages including cost-effectiveness of various medical approaches to 
glaucoma treatment, techniques employed for measuring patient compliance and actual patient 
preferences for therapy are outlined. We conclude by identifying the key barriers to ongoing 
treatment and suggest some best practices to enhance compliance and persistence.
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Primary open angle glaucoma (POAG) is a chronic, progressive optic neuropathy 
characterized structurally by optic disc and retinal nerve ﬁ  ber layer thinning and 
functionally by defects starting initially in the peripheral vision as measured by a 
visual ﬁ  eld test. Recently, glaucoma has emerged as a leading cause of irreversible 
vision loss worldwide and is an issue of major public health importance. It is estimated 
to affect 66 million people worldwide, with at least 6.8 million people bilaterally 
blind from the condition (Quigley 1996). Individuals of African ancestry have a 
higher prevalence, earlier age of onset, and often a more aggressive form of POAG 
vs Caucasian populations (Leske et al 1994; Quigley and Vitale 1997; Friedman 
et al 2004, 2006). Once diagnosed, it heralds the onset of lifelong therapy, careful 
monitoring of the optic disc and retinal nerve ﬁ  ber layer (RNFL) for damage along 
with periodic visual ﬁ  eld checks.
Currently the mainstay of treatment is reduction in intraocular pressure (IOP) 
enough to achieve a therapeutic goal termed the ‘target IOP range’ (Damji et al 2003). 
This is the level of IOP at which further optic nerve and/or visual ﬁ  eld damage is not 
expected to occur. There is now good evidence from randomized controlled trials that 
lowering IOP to target levels slows optic nerve and/or visual ﬁ  eld damage (CNTG 
1998; Kass et al 2002; Leske et al 2003; Nemesure et al 2007). IOP also appears to 
be the only risk factor that can be easily modiﬁ  ed and objectively monitored by eye Patient Preference and Adherence 2008:2 304
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care professionals such as ophthalmologists and optometrists 
thereby minimizing conversion rates of ocular hypertension 
(OHT) to glaucoma and disease progression in established 
glaucoma (CNTG 1998; Kass et al 2002; Leske et al 2003; 
Nemesure et al 2007). Besides, appropriate and timely sharing 
of target IOP with patients and physician colleagues often 
helps to strengthen therapeutic and collegial relationships.
Treatment decisions and effects 
on quality of life
Achieving target IOP range in POAG involves a ﬁ  ne balance 
between judicious use of medication and other strategies to 
lower IOP while simultaneously preserving patients’ vision 
and ensuring an acceptable overall quality of life. Treatment 
is often initiated in a stepwise fashion beginning with 
topical drug therapy (single then multidrug combinations) 
followed by laser trabeculoplasty, and if needed, ﬁ  ltering 
surgery (trabecular meshwork or Schlemm’s canal surgery, 
trabeculectomy, and implantation of shunts) aimed at draining 
aqueous humor from the eye (AAO 2005; LeBlanc 2007). 
While caregivers are typically keen on achieving target 
IOPs, using maximum tolerated medications with least 
side effect proﬁ  les and deciding on the type of surgery the 
patient should undergo lest medications fail, we ﬁ  nd our 
patients frequently have different goals. In one study, when 
82 patients were questioned about their biggest anxiety 
related to therapy, without doubt most harbored concerns 
about immediate moderate visual impairment that could 
impact their freedom and the risk of blindness (Bhargava et al 
2006). Translated to the real world situation, their anxiety 
was about inability to work in certain occupations, restric-
tions to driving and involvement in motor vehicle accidents 
(MVA), apprehension of falls and deterioration in general 
health status, and last but not the least, fear of eventual 
blindness (Haymes et al 2007). When probed further, other 
disturbing misconceptions regarding glaucoma therapy 
were revealed. About half of established glaucoma patients 
believed that symptoms would warn them of disease progres-
sion, about one-third of new patients considered blindness 
to be a common outcome of glaucoma and most patients 
thought that topical medications did not have any systemic 
side-effects (Danesh-Meyer et al 2008). In many ways, it is a 
gentle reminder that long-term therapy also entails quality of 
life (QOL) issues. A study that evaluated these QOL issues 
categorized patients mainly into two groups based on their 
main priorities as “reading and seeing detail” and “outdoor 
mobility”, the latter changing to the former with increasing 
visual ﬁ  eld loss and an increased willingness to trade time off 
for therapy thus resulting in a situation of forced compliance 
(Aspinall et al 2008). Considering this, it is remarkable 
how, the entire viewpoint of treating glaucoma has gradu-
ally changed to preserving “visual function” while ensuring 
minimal effects on QOL in terms of cost, treatment regime, 
follow-up schedules as well as socio economic burden (Janz 
et al 2001; Parikh et al 2008).
Patient education and counseling
Having said that, the role of a physician as an educator and 
counselor to bridge the overwhelming gap in knowledge 
transfer, cannot be over emphasized. It has been shown that 
educational interventions that speciﬁ  cally target improving 
levels of health literacy have a positive inﬂ  uence on subjects’ 
adherence to a therapeutic regime in terms of number of reﬁ  lls 
obtained more than any other factor such as age, ethnicity, 
gender, and economic status (Muir et al 2006; Juzych et al 
2008). These interventions can be highly successful if 
conducted at regular intervals in a support group setting as a 
structured program with an opportunity for patients to discuss 
various concerns related to disease process and treatment 
(Blondeau et al 2007; Danesh-Meyer et al 2008).
Deﬁ  nitions
Although it is obvious that successful management of POAG 
depends heavily on patient compliance with a prescribed 
treatment plan and that compliance with medications has 
shown to slow the progression of POAG, numerous research 
studies have also shown that patient behavior towards 
compliance and adherence to treatment is far from perfect 
(Shaw 2005). To this end, studies are designed to investigate 
and gauge patient noncompliance using various measures like 
patient self-reports, medication possession ratios, pharmacy 
refills claims data, medication monitors, etc, (Quigley 
et al 2007). So when patients state, “I take my eye drops 
faithfully”, how does the practitioner know that they are truly 
compliant? What is the meaning of the terms “adherence and 
persistence” that one often reads about in research studies 
and are they similar to ‘compliance’? (Best 2007).
Traditionally, most practitioners have viewed compliance 
as a more “passive” means of taking medication as opposed 
to adherence that implies a more “active” process in which 
the patient assumes an active role in making decisions 
regarding the treatment algorithm. To this end, an extensive 
literature search revealed that medication compliance and 
adherence are actually two different terms (Best 2007; Joyce 
et al 2008). Medication compliance refers to “the degree or 
extent of conformity to the recommendations of day-to-day Patient Preference and Adherence 2008:2 305
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treatment by the provider with respect to timing, dosage and 
frequency.” Worded differently it means “the extent to which 
the patient acts in accordance with the prescribed interval, and 
dose of a dosing regimen”. Hence “compliance” has more to 
do with the accuracy with which a patient follows the treat-
ment plan as opposed to the extent to which he/she continues 
the treatment, which is what “adherence” stands for.
Using this deﬁ  nition, we found that reasons for patient 
noncompliance to eye-drops can indeed be multifactorial, 
however the major factors that inﬂ  uence patient attitudes are 
frequency of application (Buller et al 2007; Robin et al 2007), 
ease of use (Nordstrom et al 2005; Robin et al 2007), comfort 
(Shibuya et al 2003), tolerability of side effects and perceived 
beneﬁ  ts (Detry-Morel 2006). For a slowly progressive, non-
life-threatening and asymptomatic disease like POAG, long 
term compliance is a signiﬁ  cant issue (Shaw 2005). Most 
indexing services like MEDLINE and PubMed, select “com-
pliance” as the primary term and “adherence” as a synonym 
and use it interchangeably. However, if the above-mentioned 
deﬁ  nitions were to be used to gauge patient medication use 
and for reporting related research, then “compliance” might 
be an appropriate term if viewed in the short term and “adher-
ence” appropriate if viewed over a longer period of time.
Persistence, on the other hand, refers to the act of 
continuing the treatment for the prescribed duration. It 
may be deﬁ  ned as “the duration of time from initiation to 
discontinuation of therapy” (Joyce et al 2008) (Figure 1). 
Consequently, this can only be measured indirectly from 
past patient records, returned emptied dropper bottles, 
prescription refill data, and observation of side effects 
characteristic to the drug prescribed eg, miotic pupils with 
pilocarpine or long eyelashes with latanoprost on repeated 
follow-up appointments (Bour et al 1993). Other ways of 
measuring patient persistence would be to directly evaluate 
patients’ IOP controlled days as opposed to a single IOP 
recording; which would deﬁ  nitely be more accurate but very 
cumbersome to perform (Schwartz and Platt 2002).
Interestingly, the National Health Service in UK prefers 
to use the term “concordance” to involve the patient in the 
treatment process so that he/she can participate with the 
provider in treatment decisions as to which course of action 
to take, and is thereby partially responsible for monitoring 
and reporting back to the team.
Choice of medical therapy
Although medical treatment for glaucoma is improving, 
there is no single perfect therapy. In our opinion, the 
characteristics of an ideal IOP-lowering eye drop would 
include: 1. Proven efﬁ  cacy in reducing IOP consistently 
over a 24-hour period to a level sufﬁ  cient to protect the optic 
nerve and visual ﬁ  eld from further damage; 2. Have minimal 
local and systemic adverse effects; 3. No tachyphylaxis and 
good tolerance over time; 4. Minimal frequency of dosage 
in order to promote full patient compliance; and ﬁ  nally, 
5. Applicability in diverse patient populations (Obstbaum 
et al 2004). To many caregivers, this would sound akin to a 
very demanding yet unrealistic list. To date, prostaglandin 
analogues (PGAs) closely fulﬁ  ll these criteria in many 
situations (ie, sustained efﬁ  cacy, and safety proﬁ  le with few 
systemic side effects. Ocular tolerability is generally good, 
but issues of conjunctival hyperemia, periorbital and iris 
pigmentation, eyelash growth, etc, do limit applicability in 
some patients).
In North America, there is a signiﬁ  cant trend towards 
prescribing PGAs as the ﬁ  rst-line monotherapy in newly 
diagnosed POAG (Mansberger et al 2007). These are the most 
recently introduced class of glaucoma drugs with superior 
IOP efﬁ  cacy, once daily dosing and with very minimal 
systemic side effects. There can however be considerable 
though not necessarily unpleasant ocular side effects. One 
study that reviewed three ophthalmology practices in Alberta, 
Canada found that compared to other ﬁ  rst- and second-line 
forms of therapy, latanoprost either alone or in combination 
with beta-blockers was associated with greater reductions in 
IOP, better therapeutic persistence, fewer therapy switches 
and lesser visits to the ophthalmologist (Tingey et al 2005). 
Notwithstanding the above, timolol (Beta-blocker), despite 
it’s contraindications and side-effect proﬁ  le, is still probably 
the most used topical glaucoma medication worldwide 
owing to its availability, lower cost, and long experience 
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Figure 1 Deﬁ  nition of compliance and persistence. Copyright © 2008.   Adapted with 
permission from Joyce AC, Ahuja R, Anita B, et al 2008. Medication compliance and 
persistence: terminology and deﬁ  nitions. Value Health, 11:44–7.Patient Preference and Adherence 2008:2 306
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(Sood et al 1991). In fact, it is one of the ﬁ  rst line medications 
for glaucoma in the developing world.
Despite the good IOP-lowering effect of PGA, some 
patients may not be well controlled on monotherapy and 
may require additional medication. This requirement for 
2 or more medications is well documented in the major 
randomized control trials such as the Ocular Hypertension 
Treatment Study where 49% of patients required more than 
one medication and the Collaborative Initial Glaucoma 
Treatment Study where 75% required supplementary 
medication. For the reader interested in the indications and 
side effects of the most commonly used antiglaucoma drugs, 
we have included the summary of the various commonly 
used antiglaucoma medications as an appendix at the end of 
the article. It is important to note that several medications 
include a dosing regimen that is two, three or even four times 
daily, thus limiting utility if patients are unable to remember 
dosing at certain times of day.
Socioeconomic burden
When it comes to evaluating the costs associated with 
long-term therapy, most studies in literature have evaluated 
the cost of glaucoma medications by assessing the number of 
drops per bottle and associated cost per drop or per treatment 
dose (Sood et al 1991; Vicente et al 2004; Rouland et al 2005a; 
Goldberg and Walt 2006; Schmier et al 2007). A leading 
study done three years ago that prospectively looked at the 
expenditure involved in treating glaucoma and OHT over 
a two-year period in France found that the average daily 
cost for latanoprost monotherapy was similar to patients 
who failed beta-blocker monotherapy and that both drugs 
together did not cost more than therapeutic combinations 
without latanoprost (Rouland et al 2005b). There are other 
cost-effectiveness models that compare one of the newer 
prostaglandin analogues with older medications or with one 
another. For instance, a newer study done in Canada suggested 
that for patients in whom timolol is not contraindicated, it 
would be preferable, from a cost-effectiveness standpoint, to 
initiate treatment with timolol and reserve the prostaglandin 
analogues as an alternative treatment or as add-on therapy for 
patients not achieving a clinical response with timolol. The 
reasons being, although latanoprost is arguably more effective 
in its IOP-lowering effects than dorzolamide, brimonidine, 
or timolol, it is also more expensive (Lachaine et al 2008). 
However, these studies are at best conﬂ  icting in their ﬁ  ndings. 
Their usefulness is limited as they generally evaluate unit 
medication costs without including differential effectiveness 
in achieving target IOP or costs associated with rectifying 
adverse effects of various therapies, and thus they provide only 
one component of real-world costs for glaucoma. Moreover, 
there is no universal standard to measure effectiveness 
outcomes including achieving IOP thresholds, IOP-controlled 
days (Schwartz and Platt 2002), percent reduction in IOP and 
quality adjusted life years (QALYs). Therefore it becomes 
a daunting task to calculate the actual total expenditure in a 
cohort population and thereby implement policy decisions 
supporting the use of one agent versus another.
Additionally, in the developing world, the algorithm of 
treatment may vary depending on factors such as patient 
affordability and availability for follow-up. A study done by 
a tertiary care center in India reported that more than 70% of 
patients who were on a 3+ drug regime for about 3 years would 
prefer lasers and surgery because of the cumbersome schedule 
and ﬁ  nancial burden (Sood et al 1991). Although latanoprost, 
travaprost, and brimonidine are effective monotherapies for 
lowering IOP in eyes with early to moderate POAG, in the long 
term primary ﬁ  ltering surgery may be a more viable option 
especially if the patient has a visually signiﬁ  cant cataract 
requiring surgery as well. Considering the paucity of resources 
and competing opportunity costs, it might be best if developing 
countries with limited resources examined best practices of 
the western world in a conservative and cost-effective manner 
(Thomas et al 2004). An example of this is the limited use of 
antimetabolites as an adjunct for primary ﬁ  ltering surgery in 
the African subcontinent. Despite this, it has been reported 
that their blebs seem to perform well for longer periods of time 
as compared to patients of African descent in North America, 
as the conjunctiva has not been scarred down by the random 
use of topical hypotensive agents, besides saving on costs 
for both antimetabolites and long years of topical therapy 
(Girma et al 2006). To aid clinical decision-making taking 
QOL into account, the American Academy of Ophthalmology 
developed by panel consensus an assessment for evaluation 
of therapy related to POAG based on available evidence and 
expert opinion. By extensive polling, speciﬁ  c guidelines were 
developed to help practitioners in making clinical decisions 
regarding switching of therapy, use of adjunctive therapy and 
assessment/ modiﬁ  cation of medical therapy with surgery as 
a primary modality of treatment (Singh et al 2008).
Barriers to compliance 
and persistence
There are numerous barriers that prevent patients from accessing 
complete treatment: psychological, socioeconomic, poor health 
literacy, inadequate information and inadequate patient-provider 
relationships. Many studies have reported multiple obstacles to Patient Preference and Adherence 2008:2 307
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adherence in the form of poor education, lack of motivation, 
forgetfulness, drop application, and other practical issues, 
together with speciﬁ  c individual and age differences. In fact 
one study classiﬁ  ed the barriers into a four category system 
and commented that patient compliance was affected by 49% 
due to social/environmental factors (lack of support, major life 
events and travel), 32% by regimen factors (complexity, costs 
and change in medication), 16% by individual patient factors 
(knowledge, memory, motivation) and 3% by medical provider 
factors (dissatisfaction, communication) (Table 1, Figure 2). 
For many patients the source of motivation for adherence is 
determined by fear of blindness coupled with a faith in drop 
efﬁ  cacy (Tsai et al 2003; Lacey et al 2008).
A recently completed multicenter study across major 
cities in Canada assessed the reasons for noncompliance in a 
questionnaire-based survey. Forgetfulness followed by travel 
was cited as the most common reason for defaulting on eye 
drop use (Kholdebarin et al 2008) (Figure 3).
Key strategies to enhance 
compliance and persistence
A number of simple yet effective changes can be implemented 
to overcome some of these barriers. For instance patients 
showed improvement in accuracy of reporting medications 
and hence compliance when given written instructions 
about their regimen, regardless of their level of education 
or number of medications (Jampel et al 2005; Kharod et al 
2006). Providing patients with an easy medication scheduler 
and reminder in the form of a handout can go long ways 
to encourage the patient to use the correct eye drops at the 
appropriate time (Figure 4). Similarly, in a highly motivated 
patient, maintenance of a medication diary can help the health 
care provider track persistence over time (Jampel et al 2005; 
Kharod et al 2006).
The use of medication monitors, alarm clocks and 
Travalert® devices has been advocated for patients who 
need reminders for therapy when traveling (NIH 2008). For 
some patients in whom manual dexterity might be compro-
mised the use of an eye guide may aid in accurate instilla-
tion of the eye drops without wastage or contamination but 
it might actually be counter productive in others (Salyani 
and Birt 2005). And although there is no straightforward 
linear relationship between complexity of eye drop regime 
and compliance, in some patients, particularly those with 
memory problems such as Alzheimer’s disease prescribing 
fewer drops may mean better compliance (Buller et al 2007). 
Table 1 Taxonomy of barriers to adherence 
Categories Sample statement
1.   Region factors
   Reﬁ  ll I only forget to take my drops when I run out.
    Cost of medication When my insurance stopped paying for my medication I didn’t take my drops.
    Complexity It was harder when I was taking four medications, now that I am taking three it is better.
   Change When  I  ﬁ  rst started taking the drops I had a harder time remembering.
    Side effects I decided to quit taking my drops because I had a bad reaction from them.
2.   Patient factors
    Knowledge/skill Sometimes I miss my eye when taking my drops.
    Memory Sometimes I just forget to take my drops.
    Motivation/health beliefs I quit taking my drops because I didn’t see beneﬁ  t to them and didn’t think they were working.
    Co-morbidity It is harder to keep track of my drops because I am taking so many other medications.
3.   Provider factors
    Dissatisfaction I quit taking my drops because I was dissatisﬁ  ed with my doctor’s care.
    Communication I stopped taking my drops because I didn’t understand initially that I need to take them forever.
4.   Situational/environmental factors
   Accountability/lack of support Living alone I had problems taking my drops; now I live with my daughter and have no problems.
    Major life events Two years ago when my wife died I had a hard time taking my drops.
   Travel/away from home When I am on vacation it is more difﬁ  cult to take my drops.
    Competing activities I miss my drops on Sunday mornings when I go to church.
    Change in routine Lifestyle changes that occur on the weekends, such as not getting up at a normal hour, cause me 
to forget to take my drops.
Note: Copyright © 2003, Lippincott Williams and Wilkins. Reproduced with permission from Tsai JC, McClure CA, Ramos SE, et al 2003. Compliance barriers in glaucoma: a 
systematic classiﬁ  cation. J Glaucoma, 12:393–8.Patient Preference and Adherence 2008:2 308
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Figure 2 Percentage distributions of adherence barriers. Copyright © 2003, Lippincott Williams and Wilkins. Reproduced with permission from Tsai JC, McClure CA, 
Ramos SE, et al 2003. Compliance barriers in glaucoma: a systematic classiﬁ  cation. J Glaucoma, 12:393–8.
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Figure 3 Reasons given by glaucoma patients for missing eye drop medication. Copyright © 2008. Reproduced with permission from Kholdebarin R, Jin Y, Campbell RJ, et al 
2008. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol, 43:454–61.Patient Preference and Adherence 2008:2 309
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As a rule, it has been found that compliance is enhanced when 
patients self-medicate. However, if there is a possibility that 
physical or mental disability might hamper the prospects of 
self-medication, then involvement of a committed family 
member or friend in the actual drop instillation process 
becomes a necessity. Other drivers of patient adherence 
to topical ocular hypotensive therapy include a healthy 
communication with professional caregivers, participating 
in appropriate educational interventions to get information 
regarding the anticipated natural history with and without 
treatment and progression of the disease and its consequences, 
understanding the risks and beneﬁ  ts of treatment in preserving 
vision-related QOL, and being able to make an informed 
choice as to available management options (Blondeau et al 
2007; Friedman et al 2008).
Conclusion
This article reviews the various medical approaches to care of 
patients with POAG. There is an overview of various methods 
to measure medication compliance and an estimation of the 
problems related to noncompliance. Emphasis has been laid 
on the importance of focusing treatment around optimizing 
patient-related QOL. Lowering IOP to target levels and 
ensuring compliance and persistency with medical therapy in 
POAG is fundamental to preventing or slowing glaucomatous 
visual loss. Similarly, simpliﬁ  cation of the treatment regimen, 
selection of medications with the fewest systemic and ocular 
side effects, and improving patient-physician relationship 
can have a signiﬁ  cant impact on preventing deterioration 
due to noncompliance. However, as there are many barriers 
to effective treatment; it is important to understand these as 
well as best practices to enhance compliance and persistency 
in a manner that keeps in mind optimal utilization of ﬁ  nite 
human and ﬁ  nancial resources for the patient, practitioner, 
and health care system. Some tips to achieve the aforemen-
tioned include:
1.  Optimal utilization of evidence-based clinical guidelines 
for therapy in POAG.
2.  Keep treatment plan straightforward and tailored to 
patient needs/preferences.
3.  Recognize early in the treatment plan the possible 
obstacles to compliance and persistence and plan 
interventions accordingly (eg, low health literacy which 
can be addressed by patient education sessions).
  MEDICATION PROFILE  
PROFIL DE MÈDICAMENT
  MEDICATION
 MEDICAMENT
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    PETIT  
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   LUNCH
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 DINER
     BEDTIME
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- Close eyes for at least 2 minutes each time after putting a drop in the eye
- Wait at least 5 minutes between drops if putting more than 1 drop in the same eye,
- Put in drops first, then ointment(s).
 Fermez les yeux pour au moins 2 minutes apres avoir mis une 
  goutte dans l'oeil, 
-
-
-
Si vous mettez plus d'une goutte dans le même oeil, attendez 
au moins 5 minutes entre les gouttes,
Mettez toujours les gouttes avant l'onguent/les onguents.
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Appendix 1
Summary of glaucoma medications
1 Adrenergic agonists
Generic Trade name Mechanism of action 
and indications
Properties Major side effects and 
precautions
Apraclonidine 0.5%–1.0% Iopidine ↓ Aqueous production
Prevents severe elevation 
of IOP following laser 
procedures
–Max effect in 4 to 5 hrs.
–Duration of effect: 12 hrs.
–↓ IOP by 25%–39%
CI: in children
Side effects: Dry mouth, lid 
elevation, allergy [more with 
Apraclonidine] sleepiness, fatigue 
headaches, Hypotension
CI: in patients with monoamine 
oxidase inhibitors)
Brimonidine 0.2% Alphagan
Alphagan P (0.15% using 
Purite as preservative)
↓ Aqueous production
↑ Uveal scleral outﬂ  ow
Elevation of IOP where 
IOP can be deleterious 
to visual function
Duration of effect: 8–12 hr
TID if monotherapy and BID 
if adjunctive. ↓ IOP by 27%
2 Beta adrenergic blockers
Generic Trade name Mechanism of action 
and indications
Properties Major side effects and precautions
Betoxolol 0.25%–0.5% 
(selective Beta-1)
Betoptic ↓ Aqueous production
Peak effect: 2 hrs
Better tolerated 
than nonselective 
but not as effective
Relative SE and CI as nonselective 
(See below)
Timolol 0.1%–0.5% 
[nonselective]
Timoptic
Timoptol
Cusimol
Washout: 2–5 wks Additive effects to 
most IOP-lowering 
agents
SE: Bradycardia
Levobunolol 0.25%–0.5% 
[nonselective]
Betagan Reduces IOP more 
than selective
Arrhythmias, heart failure, bronchospasms, 
airway obstruction, depression, masks 
hypoglycemia in IDDM
CI – Asthma, obstructive pulmonary 
disease, sinus bradycardia, heart block
3 Carbonic anhydrase inhibitors
Systemic
Generic Trade name Mechanism of action Properties Major side effects and precautions
Acetazolamide Diamox 
Diamox sequel 
Diamox retard
↓ Aqueous formation Wash-out: 3 days Major SE: Parasthesia, GIT symptoms, 
depression, ↓ libido, kidney stones, blood 
dyscrasias, metabolic acidosis, and electrolyte 
imbalance
Indicated when topical 
medication is not effective 
or feasible
May lead to hypokalemia CI: When sodium and potassium blood levels 
are depressed, in kidney and liver disease
Dose 125–250 mg QID 
or 500 mg BD for slow 
release
In sickle cell anemia
Precautions: Allergy to sulphonamides
Pregnancy and nursing mothers:   Teratogenic 
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Topical:
Generic Trade name Mechanism of action 
and indications
Properties Major side effects and precautions
Brinzolamide Azopt CAI – ↓ Aqueous formation. As monotherapy – TID Major SE: Ocular burning and discomfort, 
other SE of sulfonamides
Dorzolamide Trusopt Indicated in elevation of IOP 
where IOP can be deleterious 
to visual function
As adjunctive to topical 
beta blockers – BID
Wash-out: 1 wk
Precaution: May increase cornea edema 
in low endothelial cell count and/or 
corneal endothelia dysfunction 
(eg, Fuchs’ dystrophy)
Oral and systemic CAI not recommended
4 Parasympathomimetics [Cholinergic drugs]
Generic Trade name Mechanism of action 
and indications
Properties Major side effects and precautions
Pilocarpine 0.5 to 4% Isoptocarpine, 
pilocarpine, 
pilogel
Increases facility of out-
ﬂ  ow of aqueous direct 
action on longitudinal 
ciliary muscles
Pilo lowers IOP in 1 hr
and lasts 6–7 hrs.   Therefore 
used QID
Major SE: Intestinal cramps, brochospasms, 
miosis, pseudomyopia [upto 8D], brow ache, 
retinal detachment, ciliary spasms, increases 
pupillary block (dose dependent).
Carbachol Isoptocarbachol Indicated in elevation 
of IOP where IOP can 
be deleterious to visual 
function
Gel used QHS Major CI: Age  40 yrs, cataract, 
uveitis, NVG
Acetylcholine 1% Miochol – for 
intracameral use 
during surgery
Miochol used intracameral 
during surgery
Drug interaction:
Precautions: Axial myopia, Hx of RD 
or Rhegm. Retinal lesion
In theory, competitive 
interaction on uveoscleral 
outﬂ  ow with prostaglandins 
In practice usually not a 
problem
Wash out: 3 days
5 Prostaglandin derivatives
Generic Trade name Mechanism of action 
and indications
Properties Major side effects and precautions
Bimatoprost 0.03% Lumigan ↑ Uveal scleral outﬂ  ow IOP-lowering starts 2–4 hrs 
after adm. with peak effect 
reached within 8–12 hrs. 
Max. IOP-lowering often 
takes 3–5 wks from start
of treatment
Major SE: *Conjunctival hyperemia. 
bimatoprost-44.7%, latanoprost-27.6%, 
travoprost-49.5%
Latanoprost 0.005% Xalatan Bimatoprost may also 
increase trabecular 
outﬂ  ow
Once daily dose. Preferably 
evening
Washout can take 4–6 wks
*Burning, stinging, FB sensation, eyelash change 
[length, thickness, color] reversible after cessation
Travoprost 0.004% Travatan *CME in aphakia and pseudophakia – Co-current 
use of NSAID may reduce this
*Reactivation of herpes keratitis
*Anterior uveitis
Precautions: Must not administer these drugs 
while wearing contact lenses (CLs). But the CLs 
can be reinserted 15mins following administration
Notes: Several of the above medications are also available as various ﬁ  xed drug combinations (typically a beta blocker paired with a prostaglandin analogue, carbonic anhy-
drase inhibitor or alpha-2 agonist). In general, the adverse effects of these combinations are related to the individual drug components. *Applies to all generic drugs under 
prostaglandin derivatives.
Abbreviation: CI, contraindications; SE, side effects; CAI, carbonic anhydrase inhibitors.